

# New Venturetec

## NET ASSET VALUE - July 31, 2017

Shares issued private	4'500'000	Price: USD 23.83	USD 107'250'000
Shares issued IPO	500'000	Price: CHF 33.00 (ex.rate 1.47)	USD 11'250'000
	<b>5,000,000</b>		<b>USD 118'500'000</b>

Convertible Bond 2018: See details below

<b>Total paid in capital</b>	<b>USD</b>	<b>118'500'000.00</b>
------------------------------	------------	-----------------------

Realized gain* (since inception to date)	USD	74'994'626.11
Realized loss* (since inception to date)	USD	109'585'211.82

\*inclusive reinvestments

### Investment appreciation of current portfolio companies

Unrealized gain	USD	4'531'843.97
Unrealized loss	USD	-1'014'500.89
<b>Total appreciation</b>	USD	<b>3'517'343.08</b>

### NAV

Cost of investments	USD	29'649'433.82
Appreciation of investments	USD	3'517'343.08
Estimated value of investments	USD	<b>33'166'776.90</b>
Convertible bond 2018	USD	-15'879'204.69
Loan	USD	-6'830'534.52
Bank Loan	USD	0.00
Accrued expenses	USD	0.00
Accounts receivables	USD	51'943.84
Cash at bank	USD	1'984'084.63
<b>Estimated value</b>	USD	<b>12'493'066.15</b>
<b>NAV per share USD</b>		<b>2.50</b>
<b>NAV per share CHF</b>		<b>2.42</b>

Exchange rate USD/CHF	0.9679
<b>Closing Market Price July 31, 2017</b>	<b>CHF 2.45</b>

## New Venturetec NAV - July 31, 2017

INDUSTRY/ COMPANY	AMOUNT USD	% CAPITAL	SECURITIES	PRICE COST	PRICE REPORTED	UNREALIZED GAIN (LOSS)	TOTAL EST. VALUE	% NAV
1. Osiris Therapeutics, Inc.	23'780'932.93	80.2	4'103'301 Common Shares	5.80	6.90	4'531'843.97	28'312'776.90	80.6
2. Myriad Genetics	5'868'500.89	19.8	200'000 Shares	29.34	24.27	-1'014'500.89	4'854'000.00	13.8
<b>TOTAL</b>	<b>29'649'433.82</b>	<b>100.0</b>				<b>3'517'343.08</b>	<b>33'166'776.90</b>	<b>94.4</b>